Collaborate with us to unlock new therapeutic pathways
We believe that target and drug discovery highly benefit from collaboration
By partnering with industry leaders, research institutions and academia, we are able to turn genetic discoveries into real-world therapies. Our proprietary Cell-Seq platform gives our partners unique access to modifier genes, enabling them to unlock new therapeutic targets or enhance their pipelines with first-in-class drugs.
- Access the Cell-Seq platform via collaborations to discover modifier genes, elucidate biological pathways, understand MoA and target biology better.
- Collaborate on drug discovery and development, reducing timelines.
- Explore the therapeutic assets that we have derived from our Cell-Seq platform.
- Work with experts in genetic research, target and drug discovery.
By collaborating with industry leaders such as Alnylam, Bristol Myers Squibb and Genentech, we combine expertise, innovation, and shared vision to tackle some of the most challenging diseases. Together, we are shaping the future of medicine.
Pioneering indication selection with Bristol Myers Squibb
Our partnership with Bristol Myers Squibb is focused on leveraging Scenic Biotech’s proprietary Cell-Seq platform to unlock new therapeutic pathways for undisclosed targets of Bristol Myers Squibb’s interest. This will facilitate indication selection and expansion, and accelerate the development of such drug targets. This collaboration underscores the power of combining cutting-edge technology with industry expertise to drive meaningful progress in healthcare.
Identifying novel drug targets with Genentech
In collaboration with Genentech, Scenic Biotech is advancing the discovery of modifier genes to tackle complex diseases. Scenic utilizes its Cell-Seq platform to identify drug targets in multiple therapeutic areas of Genentech’s interest. This partnership highlights the mutual commitment to innovation and shared belief in the transformative potential of genetic research. By combining Scenic’s unique approach with Genentech’s know-how, we are opening doors to new possibilities in targeted therapies that address unmet medical needs.
New drug targets for RNAi therapeutics with Alnylam
With Alnylam Pharmaceuticals, Scenic Biotech leverages its Cell-Seq platform to discover novel targets for RNAi therapeutics. Mapping unexplored biological pathways and connecting these to actionable drug targets will form the basis for the discovery and development of novel RNAi drugs.
Discover how we can help
each other
Want to exploit the power of Scenic’s Cell-Seq platform?
We enter research collaborations for novel target identification, pathway elucidation, indication expansion or exploration of MoA for both targets and drugs. More about the platform.
Interested in novel validated drug targets?
We form drug discovery and (co-)development partnerships for our newly identified drug targets. Contact us us to discover what we can do together!
Looking for first-in-class small molecule therapeutics?
We are open to partnering and licensing discussions for our therapeutic assets in neuro- and metabolic diseases. Take a look at our pipeline.